New Haven, Connecticut-based clinical-stage biopharmaceutical company Biohaven Ltd. is devoted to identifying, developing, and bringing to market therapies that treat debilitating neurological and neuropsychiatric conditions, particularly in the United States. The firm's product portfolio includes BHV-7000, which targets focal epilepsy by activating potassium channels; BHV-7010, a Kv7 channel modulator used to treat a range of neurological diseases; and Troriluzole, a tripeptide prodrug currently in its Phase 3 trial, developed for the treatment of neurological and neuropsychiatric disorders. The company's pipeline also comprises BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist designed for neuropathic pain management, and Verdiperstat, an oral myeloperoxidase inhibitor in its Phase 3 clinical trial phase for patients with neurodegenerative illnesses. Biohaven's product offering also includes Taldefgrobep Alfa, an anti-myostatin adnectin presently undergoing Phase 3 trials as a treatment for spinal muscle atrophy, and BHV-1100 designed for treatment of multiple myeloma, currently in its Phase 1a/1b clinical trial. Previously known as Biohaven Research Ltd, the company changed its name to Biohaven Ltd. in September of this year. Biohaven Ltd. was established in 2022 and is headquartered in New Haven, Connecticut. The firm is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Company's ticker is BHVN
The company's shares trade on the NYSE stock exchange
They are based in New Haven, Connecticut
There are 501-1000 employees working at Biohaven Pharmaceutical Company
It is biohavenpharma.com
Biohaven Pharmaceutical Company is in the Healthcare sector
Biohaven Pharmaceutical Company is in the Biotechnology industry
The following five companies are Biohaven Pharmaceutical Company's industry peers: